Triumvira Reports Updated Positive Data From Ongoing Tactic-2 Phase
Triumvira Immunologics (Triumvira), A Clinical-Stage Company Developing Novel, Targeted Autologous And Allogeneic T Cell Therapeutics That Co-Opt The Natural Biology Of T Cells To Treat Patients With Cancer, Announced Updated Positive Clinical Data From Its Ongoing Tactic-2 Phase 1/2 Trial Of Tac01-Her2 In Patients With Human Epidermal Growth Factor Receptor 2 (Her2) Positive Solid Tumours Will Be Shared In A Poster At The Society For Immunotherapy Of Cancer
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!